Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Although more than 70 neuroprotective agents have failed to show unequivocal benefit in patients with acute ischemic stroke, none of those tested to date were delivered in the hyperacute phase of stroke. However, according to results from the recent Field Administration of Stroke Therapy–Magnesium (FAST-MAG) phase 3 clinical trial, administration of magnesium sulfate to patients with suspected stroke within 2 hours of symptom onset similarly failed to improve functional outcomes (Saver JL et al. N Engl J Med. 2015;372:528-536).
Slomski A. Neuroprotective Agent Given Soon After Stroke Shows No Benefit. JAMA. 2015;313(12):1200. doi:10.1001/jama.2015.2211